SEC Form 4 · accession 0001562180-17-002780
Avalo Therapeutics, Inc. · AVTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
John Joseph Kaiser
Officer — Chief Business Officer
Period of report
Aug 18, 2017
Accepted (ET)
Aug 22, 2017 · 2:01 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001534120
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Buy)F1,F2 | $0.62 | Aug 18, 2017 | A | 25,000 | A | Aug 17, 2018 | Aug 18, 2027 | Common Stock | 25,000 | 25,000 | D |
Explanation of responses
- F1One third of the shares subject to the Option shall vest on the first anniversary of the date of grant and the remaining two thirds of the shares subject to the Option shall vest in equal monthly installments on each monthly anniversary date of the first vesting date over the following 24 months beginning on 18-Aug-2017
- F2The stock options vest 1/3 at the first anniversary and 1/36th each month thereafter for the next two years.